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1279Lipoprotein(Lp)(a) is a low-density lipoprotein (LDL)-like
particle consisting of hepatically synthesized apolipoprotein
B100 that is noncovalently bound to the plasminogen-like
glycoprotein apolipoprotein(a) (1). The biological role of
Lp(a) is uncertain, but it is present only in humans, hedge-
hogs, primates, and old-world monkeys (2). Lp(a) is recog-
nized as an independent risk factor for myocardial infarction,
stroke, and peripheral arterial disease and is believed to in-
crease the risk for cardiovascular disease (CVD) via its
atherogenic LDL moiety and its prothrombotic, proin-
ﬂammatory apolipoprotein(a) moiety (3,4). Levels of Lp(a)
>125 nmol/l (approximately 50 mg/dl), the 80th percentile
for most populations, have shown a consistent and inde-
pendent positive association with CVD risk in epidemiolog-
ical studies (5,6). Recently, a large Mendelian randomization
study demonstrated that a genetically determined doubling
of Lp(a) was associated with a 22% increase in CVD risk,
suggesting a causal link (7). In addition, elevated Lp(a) is
an independent CVD risk factor in patients with familial
hypercholesterolemia (8).
Lp(a) levels are primarily genetically determined and are
dependent mainly on the rate of hepatic synthesis. Formation
of Lp(a) appears to take place at the hepatic cell surface, where
an apolipoprotein(a) kringle moiety is noncovalently linked to
LDL apolipoprotein B (9). The lower the number of kringle
IV type 2 repeats in the apolipoprotein(a) gene, the higher the
plasma level of Lp(a) (10). Clearance of circulating Lp(a) is
not well understood but is thought to occur primarily by he-
patic and renal pathways, although these metabolic routes do
not appear to govern plasma Lp(a) levels. The LDL receptor
does not appear to participate in Lp(a) clearance, reinforced by
the fact that statins, which act mainly by upregulating LDL
receptor activity, do not lower Lp(a) (11,12).
Lp(a) is relatively refractory to both lifestyle and drug
intervention, with current therapeutic options limited to
nicotinic acid, which shows consistent reductions of 15% to
25% (13,14). Studies using monoclonal antibody inhibition of
the proprotein convertase subtilisin/kexin type 9 (PCSK9)
have demonstrated reductions in Lp(a) levels, but the studies
have been of short duration with small numbers of subjects;
and relationships to dose, sex, and background lipid therapy
have not been fully established (15–17). PROFICIO (Program
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Populations), a pooled analysis of
1,359 patients from 4 phase II tri-
als, provided the ability to robustly
assess the effects of evolocumab
(AMG 145), a fully human
monoclonal antibody to PCSK9,
on Lp(a), the relationship between
Lp(a) and the lowering of LDL-C
and apolipoprotein B, and the in-
ﬂuence of factors such as sex,
baseline Lp(a), and background
statin therapy. In addition, the
open-label extension of these trials
allowed for evaluation of the
maintenance or discontinuation of
evolocumab therapy on Lp(a) levels.Methods
Study design and participants. This analysis included
patients who participated in 4 randomized, double-blind,
controlled phase II studies of evolocumab (15,18–20). The
patient populations, background lipid therapy, and treat-
ment arms in these studies were described previously and are
summarized in Table 1. All studies were of 12-week dura-
tions and examined a range of evolocumab doses and dose
frequencies administered subcutaneously (SC): 70 mg, 105
mg, or 140 mg every 2 weeks (Q2W) or 280 mg, 350 mg, or
420 mg every 4 weeks (Q4W) and were compared with
placebo (Q2W or Q4W, respectively); in 2 trials, ezetimibe
was administered, either alone or concomitantly with evo-
locumab or placebo (Fig. 1). The primary endpoint for all 4
trials was the percentage change from baseline in LDL-C at
week 12, measured by ultracentrifugation (UC LDL-C);
pooled results for this endpoint and other lipid analyses, as
well as pooled safety data, were reported separately (21).
This analysis focuses on Lp(a), including the percentage of
change from baseline at week 12 in Lp(a) by dose group and
for the patient subgroup considered to be at highest risk as
indicated by baseline Lp(a) values that exceeded 125 nmol/l
(approximately 50 mg/dl). Additional analyses included
the relationship between Lp(a) lowering and lowering of
UC LDL-C and apolipoprotein B and the effects of sex,
age, baseline LDL-C and statin therapy on Lp(a) lowering.
In addition, the phase II open-label extension study
(NCT01439880) allowed for evaluation of evolocumab
maintenance or discontinuation on Lp(a) levels during the
ﬁrst 12 weeks of follow-up for patients re-randomized to
receive either evolocumab, 420 mg Q4W, or to continue with
background lipid-lowering standard of care (SOC) therapy.
Lp(a) was measured using an isoform-independent
immunoturbidometric assay (Denka Seiken Co. Ltd., Lp(a)
assay, Polymedco, Cortlandt Manor, New York) with a
AU5400 analyzer (Olympus, Beckman Coulter Instruments,
Brea, California) (22).
Table 1 Characteristics of the 4 Evolocumab Phase II Studies
Study (Ref. #) (Method) n*
Patient Proﬁle and Background
Lipid-Lowering Therapy Treatments and Doses
Key Efﬁcacy Results
After 12 Weeks of Treatment
MENDEL (1)
(monotherapy)y
406 LDL-C 100 and <190 mg/dl
(2.6 and <4.9 mmol/l)
No background antilipid
therapy
Patients with CAD were
excluded.
9 treatment groups:
Evolocumab 70 mg, 105 mg,
or 140 mg or placebo Q2W
OR
Evolocumab 280 mg, 350 mg,
or 420 mg or placebo Q4W
OR
Daily ezetimibe 10 mg
LDL-C (UC) mean % change from baseline
vs. placebo: 37.3% to 52.5%
vs. ezetimibe: 26.7% to 34.1%
p < 0.001 for all doses
Lp(a) mean % change from baseline
vs. placebo: 11.1% (p ¼ 0.0437) to
29.2% (p < 0.001 for all doses) vs.
ezetimibe: 7.8% (p ¼ 0.13) to
26.0% (p < 0.001 for all doses)
LAPLACE-TIMI 57 (2,3) (combination
therapy) y
629 LDL-C 85 mg/dl
(2.2 mmol/l)
Statin  ezetimibe
CAD at baseline:
Evolocumab: n ¼ 145 (31%)
Placebo: n ¼ 42 (27%)
8 treatment groups:
Evolocumab 70 mg, 105 mg,
140 mg, or placebo Q2W
OR
Evolocumab 280 mg, 350 mg,
420 mg, or placebo Q4W
LDL-C (UC) mean % change from baseline
vs. placebo: 41.8% to 66.1%
(p < 0.001 for all doses)
Lp(a) mean % change from baseline vs.
placebo: 18.0% to 32.3%
(p < 0.001 for all doses)
RUTHERFORD (4) (heterozygous FH) y 167 Heterozygous FH with
LDL-C 100 mg/dl
(2.6 mmol/l)
Statin  ezetimibe
CAD at baseline:
Evolocumab: n ¼ 25 (23%)
Placebo: n ¼ 10 (18%)
3 treatment groups:
Evolocumab 350 mg, 420 mg,
or placebo Q4W
LDL-C (UC) mean % change from baseline
vs. placebo: 43.8% to 56.4%
(p < 0.001 for all doses)
Lp(a) mean % change from baseline
vs. placebo: 23.1% to 31.5%
(p < 0.001 for all doses)
GAUSS (5)
(statin intolerance) y
157 Statin-intolerant patients
LDL-C 100 mg/dl
(2.6 mmol/l)
No/low-dose statin
CAD at baseline:
Evolocumab: n ¼ 11 (12%)
Placebo: n ¼ 10 (31%)
5 treatment groups:
Evolocumab 280 mg, 350 mg,
or 420 mg Q4W
OR
Ezetimibe 10 mg plus SC
placebo Q4W
OR
Ezetimibe 10 mg plus
evolocumab
420 mg Q4W
LDL-C (UC) mean % change from baseline
vs. ezetimibe: 26.0% to 47.3%,
p < 0.001 for all doses
Lp(a) mean % change from baseline vs.
ezetimibe: 19.1% to 33.1%
*The number of patients who were randomized and received at least 1 dose of investigational product. yThe primary endpoint for each trial was percent reduction in LDL-C from baseline at week 12.
CAD ¼ coronary artery disease, based on the presence of angina, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention; FH ¼ familial hypercholesterolemia; GAUSS ¼
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects; LDL-C ¼ low-density lipoprotein cholesterol; LAPLACE-TIMI 57 ¼ LDL-C Assessment With PCSK9 Monoclonal Antibody
Inhibition Combined With Statin Therapy; MENDEL ¼ Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy for Easing Lipid Levels; Q2W ¼ every 2
weeks; Q4W ¼ every 4 weeks; PBO ¼ placebo; RUTHERFORD ¼ Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder; SC ¼ subcutaneous.
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1280Data extraction and statistical analysis. A total of 1,359
patients were enrolled, and the pooled analyses included all
randomly assigned patients who received at least 1 dose of
investigational product or placebo in the 4 phase II studies
(Fig. 1). In the Lp(a) analyses, patients randomized to receive
either ezetimibe or placebo therapy were included in the
control groups. Analyses for Lp(a), UC LDL-C, and apoli-
poprotein B were performed using the analysis of covariance
model in each dosing regimen (Q2W or Q4W), with the last
observation carried forward imputation for missing data, to
compare the efﬁcacy of evolocumab doses to those of the
control. Analyses were not controlled for multiplicity. The
correlations betweenLp(a) andUCLDL-Cor apolipoprotein
B for patients randomized to evolocumab and placebo com-
binedwere assessed using the Spearman correlation coefﬁcient
for patients with Lp(a) 5 nmol/l (the lower limit of detec-
tion) at week 12. All analyses were done with SAS/STAT
version 9.2 software (SAS Institute, Cary, North Carolina).
Results
In a population with an age of 56.4  11.7 years, 56.2%
women, and 60.3% patients taking statin therapy, themedian baseline Lp(a) concentration was 40.0 nmol/l
(interquartile range [IQR]: 13.0 to 144.0 nmol/l), and the
mean baseline UC LDL-C concentration was 140.6 
38.9 mg/dl Table 2. Evolocumab treatment resulted in
signiﬁcant (p < 0.001) dose-related mean reductions in
Lp(a) for all treatment groups compared with control
(Fig. 2, Table 3). Lp(a) reductions were accompanied by
signiﬁcant reductions from baseline in UC LDL-C and
apolipoprotein B (Table 3). Signiﬁcant correlations were
observed between percentages of reductions in Lp(a) and
UC LDL-C (Spearman correlation coefﬁcient, 0.5134;
p < 0.001) (Fig. 3A) and between reductions in Lp(a) and
apolipoprotein B (Spearman correlation coefﬁcient, 0.5203;
p < 0.001) (Fig. 3B).
Results were also analyzed according to consensus-
based “high-risk” Lp(a) levels >125 nmol/l (approxi-
mately 50 mg/dl, or the 80th percentile of the population)
(6) (Table 4). There were signiﬁcantly more patients in
the high-risk Lp(a) group with coronary artery disease
and hypertension and who were taking statins or ezeti-
mibe at baseline and who were black (Table 4). Baseline
UC LDL-C was 141.6  39.1 mg/dl and 138.2  38.8
mg/dl in the low- and high-risk groups, respectively, and
Figure 1 PROFICIO Analysis Schema
The PROFICIO analysis included pooled patient data from 4 phase II studies of evolocumab in patients receiving various background therapies. Q2W ¼ every 2 weeks;
Q4W ¼ every 4 weeks. *In the Lp(a) analysis, patients who received ezetimibe or placebo were analyzed in the control groups; the ezetimibe group was analyzed with both the
Q2W and Q4W control groups. Patients who received evolocumab, 420 mg Q4W, plus ezetimibe were included in the evolocumab 420-mg group. In the LDL-C and apoli-
poprotein B analyses, patients who received ezetimibe or ezetimibe plus placebo or evolocumab, 420 mg Q4W, plus ezetimibe were excluded. LDL-C ¼ low-density lipoprotein
cholesterol.
JACC Vol. 63, No. 13, 2014 Raal et al.
April 8, 2014:1278–88 Effect of Evolocumab on Lipoprotein(a)
1281apolipoprotein B was 110.8  25.2 mg/dl and 110.7 
25.9 mg/dl in the 2 groups.
Statistically signiﬁcant reductions (p < 0.001) in Lp(a),
UC LDL-C, and apolipoprotein B were observed with
evolocumab, regardless of patients’ baseline Lp(a) levels
(Table 5). Patients with baseline Lp(a) levels 125 nmol/L
had greater percentage reductions than controls in Lp(a)
compared to those in the high-risk group (for 140 mg Q2W:
–33.2% vs. –20.0%, respectively; for 420 mg Q4W: –28.7%
vs. –16.1%, respectively), whereas the absolute reductions
compared to those of control were substantially greater in
the high-risk Lp(a) group (for 140 mg Q2W: 34.1 nmol/l
vs. 8.9 nmol/l, respectively; for 420 mg Q4W: 38.6 nmol/l
vs. 9.7 nmol/l, respectively). Baseline Lp(a) also appeared to
have an impact on both the percentages and absolute re-
ductions versus placebo in LDL-C and apolipoprotein B,
with those with baseline Lp(a) >125 nmol/l experiencing a
lower percent reduction of approximately 6% to 8% and a
modestly smaller absolute reduction (Table 5).
There were no differences in Lp(a) responses based on
sex, age (below and at or above 65 years), or LDL-C (belowand at or above median baseline levels) (Online Fig. S1).
Reductions in Lp(a) were numerically greater in patients on
background statin therapy than in those not on statin
therapy and were statistically signiﬁcant compared to con-
trols at all doses except 70 mg Q2W. The treatment dif-
ferences between those taking statins and those not taking
statins within evolocumab doses were numerically greater,
but the interaction effects were not statistically signiﬁcant
except in the 105-mg-Q2W group (interaction, p ¼ 0.0112)
(Online Fig. S2).
For patients who were randomized to receive SOC and
stopped evolocumab therapy in the open-label extension
study, Lp(a) values returned to their pre-treatment levels.
Patients who were taking evolocumab, 420 mg Q4W, and
continued with this dosage during the open-label extension
maintained the reduction in Lp(a) as shown in Figure 4.
Overall, adverse events were reported in 56.8% and 49.2%
of patients in the combined evolocumab and combined
placebo groups, respectively, with no relationship to dose or
frequency. Serious adverse events were reported in 2.0% and
1.2% of patients in the evolocumab and placebo groups,
Table 2 Patient Demographics, Lipoprotein(a), Apolipoprotein B, and Related Lipid Parameters at Baseline
Control*
(n ¼ 378)
Evolocumab
Total
(N ¼ 1,359)
70 mg
Q2W
(n ¼ 124)
105 mg
Q2W
(n ¼ 125)
140 mg
Q2W
(n ¼ 123)
280 mg
Q4W
(n ¼ 156)
350 mg
Q4W
(n ¼ 210)
420 mg
Q4W*
(n ¼ 243)
Age, yrs 55.5 (11.4) 56.3 (11.8) 54.9 (11.6) 58.9 (11.7) 57.5 (10.7) 55.9 (13.0) 56.8 (11.8) 56.4 (11.7)
Women 214 (56.6) 74 (59.7) 58 (46.4) 81 (65.9) 86 (55.1) 117 (55.7) 134 (55.1) 764 (56.2)
Race
White 328 (86.8) 105 (84.7) 104 (83.2) 106 (86.2) 127 (81.4) 185 (88.1) 209 (86.0) 1164 (85.7)
Black 32 (8.5) 13 (10.5) 13 (10.4) 13 (10.6) 18 (11.5) 15 (7.1) 22 (9.1) 126 (9.3)
Othery 18 (4.8) 6 (4.8) 8 (6.4) 4 (3.3) 11 (7.1) 10 (4.8) 13 (5.3) 70 (5.2)
Statin use 217 (57.4) 78 (62.9) 78 (62.4) 78 (63.4) 84 (53.8) 139 (66.2) 145 (59.7) 819 (60.3)
Ezetimibe use 46 (12.2) 6 (4.8) 8 (6.4) 7 (5.7) 7 (4.5) 44 (21.0) 42 (17.3) 160 (11.8)
Lipid parameters
Lipoprotein(a) nmol/l 42.0
(14.0–144.0)
49.0
(14.0–154.0)
40.0
(12.0–151.0)
43.5
(14.0–141.0)
37.0
(12.0–130.0)
36.0
(10.0–127.0)
41.0
(14.0–160.0)
40.0
(13.0–144.0)
UC LDL-C, mg/dl 141.6 (35.6) 129.3 (25.6) 132.6 (29.6) 127.8 (25.3) 142.4 (42.4) 144.8 (42.2) 150.8 (49.4) 140.6 (38.9)
Calc LDL-C, mg/dl 140.2 (36.4) 128.1 (27.1) 130.4 (30.4) 125.5 (25.5) 140.1 (42.6) 142.7 (43.8) 148.6 (50.2) 138.7 (39.8)
Apolipoprotein B, mg/dl 111.1 (23.5) 103.1 (16.9) 105.4 (20.1) 101.9 (16.9) 112.1 (27.3) 114.3 (28.1) 117.8 (30.7) 110.8 (25.4)
Non-HDL-C, mg/dl 167.1 (41.0) 153.9 (30.2) 157.8 (34.0) 152.0 (26.8) 168.3 (47.6) 170.5 (46.9) 176.9 (54.8) 166.1 (43.7)
HDL-C, mg/dl 53.8 (16.8) 54.5 (17.1) 53.6 (17.7) 54.7 (15.1) 54.7 (17.8) 51.7 (15.3) 52.9 (17.3) 53.6 (16.7)
Triglycerides, mg/dl 136.0 (70.1) 129.1 (54.8) 137.4 (63.8) 132.7 (56.3) 140.3 (63.8) 141.8 (72.1) 141.4 (70.4) 137.6 (66.8)
Values are n (%), mean  SD, or median (interquartile range). n ¼ number of subjects randomized and dosed. *The control group includes placebo Q2W and Q4W, placebo plus ezetimibe, and ezetimibe
alone. The Q4W 420 mg group includes Q4W 420 mg plus ezetimibe. yOther race included American Indian or Alaskan native, Asian, Native Hawaiian or other Paciﬁc Islander, mixed race, and all others not
speciﬁed.
calc ¼ calculated; HDL-C ¼ high-density lipoprotein cholesterol; IQR ¼ interquartile range; LDL-C ¼ low-density lipoprotein cholesterol; Q2W ¼ every 2 weeks; Q4W ¼ every 4 weeks; SD ¼ standard
deviation; UC ¼ ultracentrifugation.
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1282respectively; none of these adverse events were considered by
the investigators to be treatment related. Anti-evolocumab
binding antibodies were observed in 1 patient takingFigure 2
Lipoprotein(a) Mean Percentage Change (95% CI)
From Baseline at Week 12
Statistically signiﬁcant mean reductions in Lp(a) were observed with all doses of
evolocumab compared with those of control. Least-squares mean differences (95%
CI) from ANCOVA model are shown with last observation carried forward (LOCF)
imputation. Treatment difference within each dose frequency group used control in
the same frequency group as the reference. *p < 0.001. Within each dose fre-
quency, the p value of the linear trend test is <0.001. ANCOVA ¼ analysis of
covariance; CI¼ conﬁdence interval; Q2W¼ every 2 weeks; Q4W¼ every 4 weeks.evolocumab and in 1 patient in the placebo group; no
neutralizing antibodies were detected.
Discussion
PROFICIO analysis conﬁrms some observations and shows
contrasts with other observations in a smaller individual trial
with a PCSK9 monoclonal antibody (17) and provides addi-
tional insights into responses by sex, age, baseline Lp(a), and
background lipid therapy. In this pooled analysis of more than
1,300 patients, evolocumab treatment resulted in highly sig-
niﬁcant dose-related reductions in Lp(a). Unlike the analysis
from the trial of evolocumab in patients with dyslipidemia
treated with statins included in this pooled analysis (17), we
demonstrate that, overall, within each dosing regimen, either
2- or 4-week dosing, there were continued reductions in Lp(a)
as the dose increased, with no plateau effect. Furthermore,
PROFICIO was differentiated in that it included a large
number of patients not taking background statin treatment,
and, although numerical reductions in treatment differences
for Lp(a) appeared to be greater with statin therapy in all dose
groups, these reductions were only statistically signiﬁcant
(p < 0.02) for the 105-mg-Q2W dosage. Signiﬁcant re-
ductions in Lp(a) compared to control were observed with
all evolocumab doses (except the lowest dosage of 70 mg
Q2W), regardless of background therapy). In addition, we
show for the ﬁrst time that the reductions in Lp(a) were both
related to treatment with evolocumab and reversible upon
discontinuation of evolocumab or maintained with continued
therapy. The PROFICIO data pool was also large enough to
provide meaningful analysis based on the consensus high-risk
Table 3 Summary of Efﬁcacy Outcomes at Week 12
Control Q2W
(n ¼ 168)
Evolocumab
Control Q4W
(n ¼ 255)
Evolocumab
70 mg Q2W
(n ¼ 124)
105 mg Q2W
(n ¼ 125)
140 mg Q2W
(n ¼ 123)
280 mg Q4W
(n ¼ 156)
350 mg Q4W
(n ¼ 210)
420 mg Q4W
(n ¼ 243)
Lipoprotein(a)*y
Absolute change from baseline, nmol/l 2.3
(7.7 to 3.2)
9.5
(15.4 to 3.6)
20.0
(25.9 to 14.1)
18.6
(24.6 to 12.5)
5.6
(10.2 to 1.0)
16.6
(22.0 to 11.1)
17.7
(22.5 to 12.9)
23.2
(27.8 to 18.6)
% change from baseline 1.7
(3.2 to 6.7)
12.1
(17.5 to 6.7)
23.5
(28.9 to 18.1)
27.8
(33.3 to 22.3)
0.1
(3.8 to 3.9)
18.6
(23.2 to 14.0)
21.3
(25.3 to 17.2)
24.5
(28.4 to 20.6)
% change vs. control d 13.8
(19.9 to 7.7)
<0.001
25.2
(31.3 to 19.1)
<0.001
29.5
(35.7 to 23.3)
<0.001
d 18.7
(23.4 to 13.9)
<0.001
21.3
(25.6 to 17.0)
<0.001
24.5
(28.7 to 20.4)
<0.001
Other related lipid parameters
UC LDL-C*y (n ¼ 123) (n ¼ 124) (n ¼ 125) (n ¼ 123) (n ¼ 178) (n ¼ 156) (n ¼ 210) (n ¼ 213)
% change from baseline 0.0
(3.7 to 3.7)
40.3
(43.9 to 36.6)
53.0
(56.6 to 49.3)
59.4
(63.1 to 55.7)
2.0
(1.7 to 5.7)
40.7
(44.5 to 36.9)
45.2
(48.6 to 41.8)
50.9
(54.3 to 47.5)
% change vs. control – 40.2
(44.6 to 35.8)
<0.001
52.9
(57.3 to 48.5)
<0.001
59.4
(63.8 to 55.0)
<0.001
d 42.8
(46.9 to 38.6)
<0.001
47.3
(51.0 to 43.5)
<0.001
52.9
(56.6 to 49.2)
<0.001
Apolipoprotein B*y (n ¼ 123) (n ¼ 124) (n ¼ 125) (n ¼ 123) (n ¼ 178) (n ¼ 156) (n ¼ 210) (n ¼ 213)
% change from baseline 3.2
(0.0 to 6.4)
30.7
(33.9 to 27.5)
41.8
(45.0 to 38.6)
49.0
(52.2 to 45.7)
2.7
(0.6 to 6.0)
31.6
(35.0 to 28.2)
35.3
(38.3 to 32.2)
40.8
(43.9 to 37.8)
% change vs. control d 33.9
(37.7 to 30.1)
<0.001
44.9
(48.8 to 41.1)
<0.001
52.1
(56.0 to 48.3)
<0.001
d 34.2
(37.9 to 30.5)
<0.001
37.9
(41.2 to 34.6)
<0.001
43.5
(46.8 to 40.2)
<0.001
n ¼ number of subjects randomized and dosed. *Least squares mean (95% conﬁdence interval) is from the analysis of covariance model, which includes the study/stratiﬁcation-combined variable and treatment as covariates. Missing values at week 12 are imputed using last
observation carried forward (LOCF) and, for UC LDL-C, calculated LDL-C. Percentage of change from baseline is the treatment difference versus control. Treatment difference within each dose frequency group uses control in the same frequency group as the reference. Note that
1 trial (GAUSS) (20) did not have a true placebo-only group. yIn the lipoprotein(a) analysis, patients who received ezetimibe or placebo were analyzed in the control group, and patients who received evolocumab 420 mg Q4W plus ezetimibe were analyzed in the evolocumab 420
mg group. In the LDL-C and apolipoprotein B analyses, patients who received ezetimibe or ezetimibe plus placebo or evolocumab 420 mg Q4W plus ezetimibe were excluded.
UC LDL-C ¼ low-density lipoprotein cholesterol measured by preparative ultracentrifugation; other abbreviations as in Table 2.
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Figure 3 Correlation of Lipoprotein(a) With LDL-C and Apolipoprotein B
Correlation of Lp(a) percentage reductions at week 12 with percentage reductions in LDL-C (A) and apolipoprotein B (B) at week 12, including evolocumab and placebo
groups combined, were statistically signiﬁcant (Spearman correlation coefﬁcients, p < 0.001). LDL-C ¼ low-density lipoprotein cholesterol.
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1284cut point above 125 mmol/l (approximately 50 mg/dl) and
that for subjects with Lp(a) above this level, evolocumab
produced absolute reductions of 35 to 40 nmol/l at the highest
doses administered, either every 2 or 4 weeks. PROFICIO
also demonstrated that baseline Lp(a) appears to have an
impact on LDL-C and apolipoprotein B response in patients
with levels>125 nmol/l experiencing approximately 6% to 8%
less LDL-C and apolipoprotein B reduction.
The statistically signiﬁcant (p < 0.001) associations
between reductions in Lp(a) and those in LDL-C and
apolipoprotein B may provide some insight into the po-
tential mechanism(s) by which PCSK9 inhibition results in
Lp(a) reduction. Lp(a) reduction could result from decreased
production or assembly, increased clearance, or a combina-
tion of both mechanisms.
As shown by Tsimikas et al. (23), Koschinsky et al. (24),
and Koschinsky and Marcovina (25), there is a stronginverse relationship between triglyceride and Lp(a) levels,
consistent with the requirement for delipidation of
triglyceride-rich forms of apolipoprotein B in the circulation
as a prerequisite for Lp(a) assembly, which likely occurs at
the cell surface and not intracellularly. Patients with defects
in very low-density lipoprotein clearance or, alternatively,
those with abetalipoproteinemia who have mutations in the
microsomal triglyceride transfer protein (MTP) gene
required for lipoprotein assembly, have very low plasma
levels of all apolipoprotein B containing lipoproteins,
including Lp(a), supporting this hypothesis (26). Further
evidence of the critical role of apolipoprotein B availability
and LDL in the formation of Lp(a) comes from reductions
in Lp(a) seen when apolipoprotein B synthesis is down-
regulated with an antisense drug (27). While a direct effect
on reducing apolipoprotein B synthesis by inhibition of
PCSK9 has not been established, the converse has been
Table 4
Baseline Characteristics, Lipoprotein(a)
 and >125 nmol/l
125 nmol/l
(n ¼ 971)
>125 nmol/l
(n ¼ 382) p Value*
Age, yrs 56.1 (11.9) 57.1 (11.3) 0.12
Women 552 (56.8) 209 (54.7) 0.48
Race <0.001
White 862 (88.8) 296 (77.5)
Black 57 (5.9) 69 (18.1)
Other 52 (5.4) 17 (4.5)
Lipid medication 568 (58.5) 262 (68.6)
Statin 558 (57.5) 258 (67.5) <0.001
Ezetimibe 90 (9.3) 70 (18.3) <0.001
Coronary artery disease 151 (15.6) 93 (24.3) <0.001
Type 2 diabetes
mellitus
88 (9.1) 43 (11.3) 0.22
Hypertension 460 (47.4) 216 (56.5) 0.002
Lipid parameters
Lipoprotein(a), nmol/l 22.0 (9.0–49.0) 196.0 (165.0–253.0)
UC LDL-C, mg/dl 141.6 (39.1) 138.2 (38.8) 0.16
Apolipoprotein B,
mg/dl
110.8 (25.2) 110.7 (25.9) 0.94
HDL-C, mg/dl 52.8 (16.2) 55.6 (18.0) 0.006
Triglycerides, mg/dl 141.7 (70.2) 126.2 (55.1) 0.001
PCSK9, ng/mL 421.2 (137.7) 444.1 (154.8) 0.009
Values are (%), mean  SD, or median (interquartile range). n ¼ number of subjects randomized
and dosed in respective subgroup. *p values were assessed as univariate predictors of baseline
Lp(a) >125 nmol/l.
PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; other abbreviations as in Table 2.
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increases apolipoprotein B synthesis independently of the
decreased uptake of LDL/apolipoprotein B by the LDLFigure 4
Longer-term Effects of Evolocumab Maintenance
or Discontinuation
Longer-term effect of evolocumab maintenance or discontinuation on Lp(a)
changes are shown during 12 weeks of the phase II open-label extension, median,
and IQR values. EOS ¼ end of original study; IQR ¼ interquartile range; Q2W ¼
every 2 weeks; Q4W ¼ every 4 weeks; SOC ¼ standard of care.receptor. These ﬁndings may lend support to the notion that
either reduced apolipoprotein B synthesis or decreased
LDL-apolipoprotein B availability, or both, could lead to
reduced Lp(a) formation (28–30).
It is known that apolipoprotein(a), once cleaved from
LDL-apolipoprotein B, is degraded by elastases and pro-
teases, and the resultant fragments are excreted in urine,
where they can be measured (9). As patients with advanced
renal failure have increased Lp(a) levels, usually made up of
large isoforms, there does appear to be a signiﬁcant role for
the kidney in Lp(a) clearance (9). Thus, if there were a
reduction in Lp(a) formation due to decreased LDL-
apolipoprotein B availability subsequent to the marked fall
in LDL associated with PCSK9 inhibition with evolocumab,
an increase in “free” apolipoprotein(a) would occur if apoli-
poprotein(a) synthesis rates remained constant, resulting in
increased urinary excretion of intact apolipoprotein(a) or its
fragments. Future studies with PCSK9 inhibitors should
assess this by measurements in pre- and post-treated patients.
Mechanisms for clearance of Lp(a) are not well established,
and no known speciﬁc receptors or pathways have been
validated. Studies assessing clearance of radiolabeled Lp(a) in
both rodents and humans with LDL receptor defects do not
support a signiﬁcant role for the LDL receptor (12). Clinical
evidence for the role of the LDL receptor is, however, con-
ﬂicting as patients with heterozygous and especially homo-
zygous familial hypercholesterolemia (FH) have higher levels
of Lp(a) than non-FH populations and their relatives with
similar Lp(a) isoforms (31). Numerous trials with drugs that
upregulate LDL receptor activity, especially statins, have
shown no or minimal reduction in Lp(a) (13). Approximately
10% to 15% of Lp(a) is converted to LDL when apolipo-
protein(a) is cleaved, and this LDL could then be cleared
more rapidly with PCSK9 inhibition as LDLR activity is
markedly enhanced (13). This may contribute to the reduc-
tion in Lp(a) when LDL levels are very low.
There are currently no approved pharmacological agents
to speciﬁcally lower plasma Lp(a) levels without affecting
other lipoproteins. Of the lipid-altering drugs approved for
LDL-C reduction in the general population, only nicotinic
acid has been shown to consistently reduce Lp(a) (14,32).
Reductions in Lp(a) were reported with therapeutic agents
recently approved under very strict prescribing guidelines for
the sole indication of treating homozygous familial hyper-
cholesterolemia (33,34), such as antisense oligonucleotides
to apolipoprotein B (mipomersen), and MTP inhibitors
(lomitapide). However, the effect with lomitapide appeared
to be lost after 78 weeks. Drugs that inhibit cholesteryl ester
transfer protein (CETP), either in development or termi-
nated due to toxicity or lack of efﬁcacy on cardiovascular
endpoints, such as torcetrapib, dalcetrapib, anacetrapib and
evacetrapib (35), have also been shown to reduce Lp(a). The
hepatic thyroid analog eprotirome also reduced Lp(a), but
development was recently terminated due to toxicity (36).
For both drug classes, the mechanism for Lp(a) reduction
remains unclear (37).
Table 5 Lipoprotein(a), UC LDL-C, and Apolipoprotein B Response by Speciﬁc Lipoprotein(a) Cut-Points at Week 12, Change and Percentage of Change Versus Control*
Dose Frequency Evolocumab Q2W Evolocumab Q4W
Dose 70 mg 105 mg 140 mg 280 mg 350 mg 420 mg
Lipoprotein(a)y
Baseline Lp(a), 125 nmol/l Absolute change from baseline vs. controlz 5.2
(9.0 to 1.4)
<0.001
9.0
(12.7 to 5.2)
<0.001
8.9
(12.7 to 5.0)
<0.001
7.0
(9.9 to 4.0)
<0.001
8.0
(10.7 to 5.4)
<0.001
9.7
(12.3 to 7.0)
<0.001
% change from baseline vs. control 16.1
(23.8 to 8.5)
<0.001
27.6
(35.2 to 20.0)
<0.001
33.2
(40.9 to 25.4)
<0.001
21.0
(27.0 to 15.1)
<0.001
25.3
(30.6 to 20.0)
<0.001
28.7
(34.0 to 23.5)
<0.001
Baseline Lp(a), >125 nmol/l Absolute change from baseline vs. controlz 16.0
(36.5 to 4.5)
0.12
39.6
(60.6 to 18.5)
<0.001
34.1
(54.9 to 13.3)
0.002
25.3
(43.4 to 7.3)
0.006
26.1
(42.5 to 9.6)
0.002
38.7
(53.9 to 23.
<0.001
% change from baseline vs. control 7.5
(16.7 to 1.8)
0.11
17.4
(26.9 to 7.9)
<0.001
20.0
(29.4 to 10.6)
<0.001
11.8
(18.9 to 4.6)
0.001
11.1
(17.6 to 4.6)
<0.001
16.1
(22.1 to 10.0)
<0.001
Interaction p value for % change by
baseline lipoprotein(a) >125 or 125 nmol/l{
0.247 0.006
LDL-C
Baseline Lp(a), 125 nmol/l Absolute change from baseline vs. controlz 52.4
(60.4 to 44.3)
<0.001
71.2
(79.2 to 63.1)
<0.001
77.9
(86.0 to 69.8)
<0.001
61.5
(69.4 to 53.5)
<0.001
64.2
(71.22 to 57.1)
<0.001
75.1
(82.3 to 67.8)
<0.001
% change from baseline vs. control 41.1
(46.6 to 35.5)
<0.001
53.7
(59.3 to 48.2)
<0.001
61.7
(67.2 to 56.1)
<0.001
46.8
(51.7 to 42.0)
<0.001
48.6
(52.9 to 44.2)
<0.001
54.7
(59.1 to 50.3)
<0.001
Baseline Lp(a), >125 nmol/l Absolute change from baseline vs. controlz 48.7
(58.6 to 38.8)
<0.001
68.4
(78.4 to 58.4)
<0.001
67.0
(76.9 to 57.0)
<0.001
45.9
(58.7 to 33.2)
<0.001
59.0
(70.7 to 47.2)
<0.001
65.9
(77.1 to 54.8)
<0.001
% change from baseline vs. control 38.3
(45.3 to 31.2)
<0.001
54.0
(61.1 to 46.8)
56.2
(63.2 to 49.1)
<0.001
34.8
(42.9 to 26.7)
<0.001
43.4
(50.8 to 35.9)
48.2
(55.3 to 41.2)
<0.001
Interaction p value for % change by baseline
lipoprotein(a) >125 or 125 nmol/l{
0.554 0.113
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1287Study limitations. It remains unknown whether lowering
Lp(a) will yield clinical beneﬁt and reduce cardiovascular
mortality. Nevertheless, the strong epidemiologic and ge-
netic evidence suggesting that Lp(a) is an independent
causal risk factor for CVD makes it a valid interventional
target for therapy when attempting to further reduce CVD
risk. Deﬁnitive outcome trials are likely to be very difﬁcult as
all current drug strategies do not reduce Lp(a) selectively but
affect multiple other lipoprotein classes. In addition to the
marked reduction in LDL-C, the reduction in Lp(a) seen
with evolocumab may be of greater beneﬁt to patients with
increased levels of this risk factor. However the apparent 6%
to 8% less LDL-C and apolipoprotein B reduction seen in
patients with elevated Lp(a) will make it very difﬁcult to
isolate the impact on CVD risk of Lp(a) reduction by
PCSK9 inhibitors in any clinical trial.Conclusions
Inhibition of PCSK9 with evolocumab yielded signiﬁcant
dose-related reductions in Lp(a) with both 2- and 4-week
dosing. The reductions were both reversible upon discon-
tinuation of evolocumab and sustained during longer-term
therapy. The reductions were independent of age, sex and
baseline LDL-C and tended to be greater in those on statin
background therapy than those on diet alone. Although
percentage reductions from baseline were greater in those
with lower starting Lp(a) levels, the absolute reductions were
substantially greater in those considered at higher risk, with
baseline Lp(a) >125 nmol/l. Those with higher baseline
Lp(a) levels had 6% to 8% less LDL-C and apolipoprotein
B reduction than those with Lp(a) in the normal range.
The reductions in Lp(a) demonstrated strong correlation
with reductions in LDL-C and apolipoprotein B, but the
mechanism by which PCSK9 reduces Lp(a) remains to be
elucidated.
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